The Library
Tumour detection in syndromic NET (carcinoid syndrome)
Tools
Tools
Tools
Dimitriadis, Georgios K. and Kaltsas, G. (2016) Tumour detection in syndromic NET (carcinoid syndrome). In: Colao W. , A. and Faggiano, A. and de Herder, W., (eds.) Neuroendocrine Tumors in Real Life. Cham, Switzerland: Springer , pp. 161-169. ISBN 9783319590226
Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1007/978-3-319-59024-0_10
Abstract
Many gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) secrete biologically active substances and can present with distinct clinical syndromes related to their oversecretion. In particular, carcinoid syndrome (CS) is a compendium of clinical manifestations including secretory diarrhoea, flushing and less commonly wheezing and dyspnoea secondary to overproduction of such compounds, mainly serotonin. Carcinoid syndrome is almost exclusively derived from small intestinal NETs that have metastasized to the liver and may also be associated with extensive fibrosis of heart valves and the mesenterium. Although the diagnosis is usually delayed due to the lack of tumour-specific symptoms, measurement of specific tumour metabolites such as 5-hydroxyindoloacetic acid facilitates the diagnosis. Conventional radiology and functioning imaging modalities using specific and occasionally non-specific tracers are used to identify the extent of disease and also provide information regarding prognosis and the application of specific treatment. The development though of diagnostic and predictive biomarkers that would allow for individualized workup and selection of specific treatments remains a priority in the field.
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
